Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 15/20 | 0.50 |
| ▸ | BACE2 | Q9Y5Z0 | 8/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | APP | P05067 | 4/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CTSE | P14091 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7943350 | 0.92 | BACE1 (0.46) | BACE1BACE2ALDH1A1MEN1KMT2A | |
| SCHEMBL7935604 | 0.90 | BACE1 (0.49) | BACE1BACE2APPCYP2D6 | |
| SCHEMBL7944846 | 0.88 | BACE1 (0.49) | BACE1BACE2 | |
| SCHEMBL7941882 | 0.86 | BACE1 (0.47) | BACE1BACE2ALDH1A1MEN1KMT2A | |
| SCHEMBL7944492 | 0.86 | BACE1 (0.58) | BACE1ALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL7946709 | 0.85 | BACE1 (0.51) | BACE1BACE2APPCYP3A4 | |
| SCHEMBL7945287 | 0.85 | GRM4 (0.48) | BACE1BACE2CYP2D6CYP3A4 | |
| SCHEMBL7934095 | 0.85 | PTGS1 (0.49) | — | |
| SCHEMBL7945260 | 0.83 | BACE1 (0.45) | BACE1BACE2KCNH2 | |
| SCHEMBL7941823 | 0.82 | BACE1 (0.46) | BACE1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110237576-A1 | 2-AMINOPYRIMIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVES BOTH HAVING BACE1-INHIBITING ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2011-09-29 | — | — | US | disclosed |
| WO-2010047372-A1 | 2-AMINOPYRIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVE BOTH HAVING BACE1-INHIBITING ACTIVITY | 塩野義製薬株式会社 (JP) | 2010-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237576-A1 | 2-AMINOPYRIMIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVES BOTH HAVING BACE1-INHIBITING ACTIVITY | BACE1, APP, BACE2 | BACE1 1/4885BACE2 3/4885ALDH1A1 1101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.